VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) — invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation in three upcoming industry and investor conferences: BIO- Europe, Inv€$tival Showcase and the Jefferies 2022 London Healthcare Conference.
BIO Europe
24-26 October 2022, Leipzig, Germany
Peter Llewellyn-Davies, CEO, and Dr. Romana Gugenberger, CMSO, will be on site and available for meetings. Peter Llewellyn-Davies will also speak at a panel discussion on innovation in the life sciences sector in Austria.
A digital company presentation by Peter Llewellyn-Davies is now available online via the event partnering system.
panel discussion: “Austria – Where innovation moves mountains!”
October 24 at 2:00 p.m. CEST, Exhibition Hall Stage
To request a meeting at the event in Leipzig or during the virtual partnering from November 1st to 4th, please use the partneringONE® system.
Investment Showcase
November 14, 2022, London
Peter Llewellyn Davies and Dr. Mario Kuttke, Head of Cell Therapy, will be in London and available for one-on-one sessions. Peter Llewellyn-Davies will present invIOs’ cell therapy platform, EPiC, and the pipeline of late-stage biotech growth-stage clinical and pre-clinical assets.
company presentation: 14 November at 14:15 GMT
To request a meeting with invIOs please use the LSX 1:1 partnering system.
Jefferies 2022 London Health Conference
15-17 November 2022, London
Peter Llewellyn Davies and Dr. Mario Kuttke will attend the conference and will be available for briefings. To schedule a meeting, please contact your Jefferies representative.
About invIOs
invIOs is a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative anti-cancer immunotherapies.
EPiC, invIOs’ proprietary cell therapy platform for intracellular modification of gene expression, enables rapid ambulatory treatment of patients with their own fresh immune cells….
